Friday, 19 Jul 2019

You are here

Hydroxychloroquine Underperforms in a Cutaneous Lupus Trial

Hydroxychloroquine has become a mainstay in the treatement of patients with systemic lupus erythematosus (SLE) with proven efficacy in managing many domains of lupus, including skin, joint, and other autoimmune features.

Arthritis & Rheumatology has published a a double-blind, randomized, placebo-controlled, parallel-group study of hydroxychloroquine (HCQ) in 103 patients with active cutaneous lupus (CLE) based on an inclusion Cutaneous Lupus Erythematosus Disease Area and Severity Index [CLASI] activity score of ≥4.

Patients received either HCQ or PBO in a 3:1 ratio for 16 weeks and then HCQ for the following 36-week single-blind period. The primary efficacy end point was a reduction in the CLASI activity score at week 16.

The CLASI score at week 16 was significantly improved in both the HCQ and the placebo groups; moreso in the HCQ group (CLASI change −4.6; 95% CI −6.1, −3.1) (P < 0.0001), than the PBO group (change −3.2; 95% CI −5.1, −1.3) (P = 0.002). Yet there was no significant between-group difference (P = 0.197).

Nonetheless, the physicians global assessment demonstrated a greater proportion of “improved” and “remarkably improved” patients in the HCQ group (51.4% versus 8.7%; P = 0.0002 between groups).  

While these results show the efficacy and tolerability of HCQ in patients with CLE, they are less than expected.  But there are several issues with this Japanese cohort that may explain these marginally effective results. First the patients were older (mean age >40 yrs), had long-standing chronic CLE, 36-46% were on background immunosuppressives (including tacrolimus and dapsone) and over half were active smokers.

Are these reflective of actual practices and real life experiences?  Study design and cohort inclusion will usually shape the outcomes of any trial and the clinical question it attempts to answer.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Cardiovascular Disease Increased in Hospitalized Lupus Patients

Systemic lupus erythematosus (SLE) patients who are hospitalized have an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) and its individual phenotypes of coronary artery disease (CAD), peripheral artery disease (PAD), and cerebrovascular disease. 

Pregnancy Outcomes Improve in Lupus

Pregnancy for patients with lupus has long been considered high risk and associated with both medical and obstetric complications, but outcomes have improved over the last 2 decades and continue to improve. The large decline in in-hospital maternal mortality was greater for lupus pregnancies than for non-lupus pregnancies. Findings from a retrospective cohort study are published in Annals of Internal Medicine.

Blinded by the Use of Antimalarials in Lupus?

Editor's note: July 1 - 5, RheumNow is running the best of EULAR 2019 meeting. Hydroxychloroquine (HCQ) will decrease SLE flares improve lipids, decrease clots, improve survival, augment the response to mycophenolate and are the cornerstone of treatment as per the SLE EULAR guidelines presented at EULAR 2019 in Madrid and also published in ARD. But, if you prescribe them long term, will your patients go blind?

Disparities in Lupus Survival

MMWR has published the outcomes from the Georgia Lupus Registry between 2002 and 2016, finding that black women were not only more likely to die from lupus than white lupus patients; but they died on average 13 years earlier (mean age 51.8 and 52.3 years, respectively) than whites (mean age 64.4 and 65.0 years, respectively). Black women with lupus were 3.34 times more likely to die than black women in the general population, while white women with lupus were 2.43 times more likely to die than white women in the general population. None of the white women with lupus died within 5 years of diagnosis, while mortality was elevated for black women from the date of diagnosis on.

DMARD Success in Myositis-Related Interstitial Lung Disease

It is estimated that up to 50% of patients with idiopathic inflammatory myopathy will be complicated by interstitial lung disease, and having ILD may impart a poor prognosis. A recent review of the Johns Hopkins myositis-related ILD cohort has shown that azathioprine and mycophenolate mofetil use is associated improved lung function and less prednisone use.